NanoPET imaging of [18F]fluoromisonidazole uptake in experimental mouse tumours

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 33, Issue 3, 2006, Pages 311-318

  Wyss, Matthias T ^a,b   Honer, Michael ^a   Schubiger, Pius A ^a   Ametamey, Simon M ^a  

^a ETH Zurich   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

18F Fluoromisonidazole 18F Fluorodeoxyglucose; Murine tumour models; NanoPET; Tumour hypoxia

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; TRACER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DRUG UPTAKE; FEASIBILITY STUDY; FEMALE; GLUCOSE METABOLISM; HUMAN; HYPOXIA; IMAGING; ISOGRAFT; MEASUREMENT ERROR; MELANOMA; MOUSE; MOUSE STRAIN; NANOTECHNOLOGY; NONHUMAN; OBSERVER VARIATION; PARAMETER; PERFORMANCE; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVITY; TUMOR; TUMOR VOLUME; XENOGRAFT;

ANIMALS; CELL HYPOXIA; EQUIPMENT DESIGN; EQUIPMENT FAILURE ANALYSIS; FEASIBILITY STUDIES; FEMALE; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED BALB C; MICE, NUDE; MISONIDAZOLE; NANOTECHNOLOGY; NEOPLASMS, EXPERIMENTAL; OXYGEN; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 33644979083     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-005-1951-4     Document Type: Article

References (57)

1. Adam MF, Gabalski EC, Bloch DA, Oehlert JW, Brown JM, Elsaid AA, et al. Tissue oxygen distribution in head and neck cancer patients. Head Neck 1999;21:146-53
2. 18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996;36:417-28
3. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;38:285-9
4. Knowles HJ, Harris AL. Hypoxia and oxidative stress in breast cancer. Hypoxia and tumourigenesis. Breast Cancer Res 2001;3:318-22
5. Valk PE, Mathis CA, Prados MD, Gilbert JC, Budinger TF. Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med 1992;33:2133-7
6. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953;26:638-48
7. Horsman MR, Overgaard J. Overcoming tumour radiation resistance resulting from acute hypoxia. Eur J Cancer 1992;28A:717-8
8. 2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993;26:45-50
9. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996;56:941-3
10. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47
11. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509-15
12. Cater DB, Silver IA. Quantitative measurements of oxygen tension in normal tissues and in the tumours of patients before and after radiotherapy. Acta Radiol 1960;53:233-56
13. 2 electrode measurements. Influence of tumour volume and carbogen breathing. Acta Oncol 2002;41:304-12
14. Achermann RE, Ohlerth SM, Rohrer Bley C, Gassmann M, Inteeworn N, Roos M, et al. Oxygenation of spontaneous canine tumors during fractionated radiation therapy. Strahlenther Onkol 2004;180:297-305
15. Nordsmark M, Loncaster J, Chou SC, Havsteen H, Lindegaard JC, Davidson SE, et al. Invasive oxygen measurements and pimonidazole labeling in human cervix carcinoma. Int J Radiat Oncol Biol Phys 2001;49:581-6
16. Buchler P, Reber HA, Lavey RS, Tomlinson J, Buchler MW, Friess H, et al. Tumor hypoxia correlates with metastatic tumor growth of pancreatic cancer in an orthotopic murine model. J Surg Res 2004;120:295-303
17. Olive PL, Aquino-Parsons C. Measurement of tumor hypoxia using single-cell methods. Semin Radiat Oncol 2004;14:241-8
18. 18F]fluoromisonidazole PET and immunohistochemistry. Br J Cancer 2004;91:1947-54
19. Evans SM, Judy KD, Dunphy I, Jenkins WT, Nelson PT, Collins R, et al. Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. Cancer Res 2004;64:1886-92
20. Evans SM, Hahn S, Pook DR, Jenkins WT, Chalian AA, Zhang P, et al. Detection of hypoxia in human squamous cell carcinoma by EF5 binding. Cancer Res 2000;60:2018-24
21. Koh WJ, Rasey JS, Evans ML, Grierson JR, Lewellen TK, Graham MM, et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992;22:199-212
22. 18F-EF5. Eur J Nucl Med Mol Imaging 2003;30:259-66
23. 18F]-EF5, a marker for PET detection of hypoxia: synthesis of precursor and a new fluorination procedure. Appl Radiat Isot 2001;54:73-80
24. Yang DJ, Wallace S, Cherif A, Li C, Gretzer MB, Kim EE, et al. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology 1995;194:795-800
25. 18F]FMISO in an experimental mammary carcinoma. Eur J Nucl Med Mol Imaging 2004;31:513-20
26. 18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol 2003;30:317-26
27. 18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography. Br J Cancer 2004;90:2232-42
28. Rischin D, Peters L, Hicks R, Hughes P, Fisher R, Hart R, et al. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19:535-42
29. 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005;46:253-60
30. 2O. J Nucl Med 2004;45:1851-9
31. Chatziioannou AF. PET scanners dedicated to molecular imaging of small animal models. Mol Imaging Biol 2002;4:47-63
32. Schafers KP. Imaging small animals with positron emission tomography. Nuklearmedizin 2003;42:86-9
33. Myers R, Hume S. Small animal PET. Eur Neuropsychopharmacol 2002;12:545-55
34. Zanzonico P, O'Donoghue J, Chapman JD, Schneider R, Cai S, Larson S, et al. Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning. Eur J Nucl Med Mol Imaging 2004;31:117-28
35. Wen B, Burgman P, Zanzonico P, O'Donoghue J, Cai S, Finn R, et al. A preclinical model for noninvasive imaging of hypoxia-induced gene expression; comparison with an exogenous marker of tumor hypoxia. Eur J Nucl Med Mol Imaging 2004;31:1530-8
36. 18F] fluoromisonidazole. Appl Radiat Isot 1993;44:1085-91
37. Jeavons AP, Chandler RA, Dettmar CAR. A 3D HIDAC-PET camera with submillimetre resolution for imaging small animals. IEEE Trans Nucl Sci 1999;46:468-73
38. Missimer J, Madi Z, Honer M, Keller C, Schubiger A, Ametamey SM. Performance evaluation of the 16-module quad-HIDAC small animal PET camera. Phys Med Biol 2004;49:2069-81
39. Reader AJ, Erlandsson K, Flower MA, Ott RJ. Fast accurate iterative reconstruction for low-statistics positron volume imaging. Phys Med Biol 1998;43:835-46
40. Mikolajczyk K, Szabatin M, Rudnicki P, Grodzki M, Burger C. A JAVA environment for medical image data analysis: initial application for brain PET quantitation. Med Inform (Lond) 1998;23:207-14
41. 18F-fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumours. Radiother Oncol 2003;67:339-44
42. Prekeges JL, Rasey JS, Grunbaum Z, Krohn KH. Reduction of fluoromisonidazole, a new imaging agent for hypoxia. Biochem Pharmacol 1991;42:2387-95
43. 18F]-2-fluoro-2′- deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia. Strahlenther Onkol 2004;180:616-22
44. 18F]fluoro-2-deoxy-D-glucose. Acta Oncol 2000;39:629-37
45. Adam MF, Dorie MJ, Brown JM. Oxygen tension measurements of tumors growing in mice. Int J Radiat Oncol Biol Phys 1999;45:171-80
46. 18F]fluoromisonidazole uptake on oxygen delivery and tissue oxygenation in the porcine liver. Nucl Med Biol 2000;27:693-700
47. Kubota K, Tada M, Yamada S, Hori K, Saito S, Iwata R, et al. Comparison of the distribution of fluorine-18 fluoromisonidazole, deoxyglucose and methionine in tumour tissue. Eur J Nucl Med 1999;26:750-7
48. Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med 1995;22:265-80
49. Rasey JS, Grunbaum Z, Magee S, Nelson NJ, Olive PL, Durand RE, et al. Characterization of radiolabeled fluoromisonidazoleas a probe for hypoxic cells. Radiat Res 1987;111:292-304
50. Ballinger JR, Kee JW, Rauth AM. In vitro and in vivo evaluation of a technetium-99m-labeled 2-nitroimidazole (BMS181321) as a marker of tumor hypoxia. J Nucl Med 1996;37:1023-31
51. Biskupiak JE, Krohn KA. Second generation hypoxia imaging agents. J Nucl Med 1993;34:411-3
52. Seddon BM, Maxwell RJ, Honess DJ, Grimshaw R, Raynaud F, Tozer GM, et al. Validation of the fluorinated 2-nitroimidazole SR-4554 as a noninvasive hypoxia marker detected by magnetic resonance spectroscopy. Clin Cancer Res 2002;8:2323-35
53. Pedersen MW, Holm S, Lund EL, Hojgaard L, Kristjansen PE. Coregulation of glucose uptake and vascular endothelial growth factor (VEGF) in two small-cell lung cancer (SCLC) sublines in vivo and in vitro. Neoplasia 2001;3:80-7
54. Minn H, Clavo AC, Wahl RL. Influence of hypoxia on tracer accumulation in squamous-cell carcinoma: in vitro evaluation for PET imaging. Nucl Med Biol 1996;23:941-6
55. 18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 2004;10:2245-52
56. Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF, et al. Biologic correlates of (18) fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002;20:379-87
57. 18F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging 2003;30:695-704